A new nasal spray developed by researchers at Texas A&M University shows promise in reversing age-related brain inflammation linked to dementia, offering a potential non-invasive approach to preventing cognitive decline. The treatment, administered as a simple spray into the nose, targets a biological process known as neuroinflammaging — chronic, low-grade inflammation in the brain that accumulates with age and contributes to memory loss and neurodegenerative diseases like Alzheimer’s.
The research, published in the Journal of Extracellular Vesicles, focuses on using cell-derived extracellular vesicles delivered via intranasal administration to reduce oxidative stress and restore mitochondrial function in aging brains. In experiments with mice equivalent to 60-year-old humans, the treatment successfully decreased markers of brain inflammation and improved cellular energy production, suggesting a mechanism by which the spray could protect against dementia onset.
Neuroinflammaging has long been considered an inevitable part of aging, but this study challenges that assumption by demonstrating that the process may be reversible through targeted intervention. By delivering therapeutic vesicles directly to the brain through the nasal passage — a route that bypasses the blood-brain barrier — the approach allows for precise targeting of affected neural tissues without systemic side effects.
The study’s lead researcher, Dr. Ashok Shetty of the Texas A&M College of Medicine, explained that the nasal spray works by introducing extracellular vesicles derived from young, healthy cells. These vesicles carry anti-inflammatory molecules and genetic material that help reprogram aged brain cells to function more like their younger counterparts, effectively resetting aspects of brain aging at the molecular level.
While the results are promising, the research remains in the preclinical stage, having been tested only in animal models so far. Human clinical trials will be necessary to determine safety, optimal dosing, and effectiveness in preventing or treating dementia in people. Researchers note that if successful in humans, such a treatment could be administered easily and regularly, much like a vaccine or allergy spray, making it accessible for widespread preventive use.
The World Health Organization estimates that over 55 million people worldwide live with dementia, a number expected to rise to 78 million by 2030 and 139 million by 2050. Alzheimer’s disease accounts for 60–70% of these cases, placing immense strain on healthcare systems and families. Any intervention capable of delaying onset or reducing risk could have significant public health implications.
Experts caution that while intranasal delivery is a growing area of interest for neurological treatments — including therapies for migraine, stroke, and neurodegenerative diseases — more research is needed to understand long-term effects and durability of benefit. The nasal route offers advantages in terms of non-invasiveness and direct brain access, but variability in absorption and individual anatomy may influence outcomes.
Funding for the study came from institutional grants supporting research into aging and neurodegenerative diseases, though specific funding bodies were not detailed in the published paper. The research team has indicated plans to pursue further preclinical testing before advancing to human trials, with the ultimate goal of developing a clinically approved therapy for age-related cognitive decline.
As scientific interest grows in modifying the biological processes of aging rather than merely treating symptoms, approaches like this nasal spray represent a shift toward preventive neurology. By targeting root causes such as chronic inflammation and cellular dysfunction, such interventions aim not just to slow dementia but to preserve brain health earlier in life.
For now, the findings offer hope that one day, a simple spritz into the nose could help keep the mind sharp — though experts emphasize that proven strategies like regular physical activity, a balanced diet, cognitive engagement, and vascular risk management remain essential pillars of dementia prevention.
Readers interested in following developments in dementia research and preventive neurology can consult updates from reputable sources such as the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed journals like JAMA Neurology and The Lancet Neurology for verified, up-to-date information.
What are your thoughts on emerging preventive treatments for dementia? Have you or someone you know explored lifestyle or medical approaches to support brain health? Share your experiences and questions in the comments below — we welcome thoughtful discussion on this important topic.
Worth a look